98%
921
2 minutes
20
Background: H-NMR metabolomics and DNA methylation in blood are widely known biomarkers predicting age-related physiological decline and mortality yet exert mutually independent mortality and frailty signals.
Methods: Leveraging multi-omics data in four Dutch population studies (N = 5238, ∼40% of which male) we investigated whether the mortality signal captured by H-NMR metabolomics could guide the construction of DNA methylation-based mortality predictors.
Findings: We trained DNA methylation-based surrogates for 64 metabolomic analytes and found that analytes marking inflammation, fluid balance, or HDL/VLDL metabolism could be accurately reconstructed using DNA-methylation assays. Interestingly, a previously reported multi-analyte score indicating mortality risk (MetaboHealth) could also be accurately reconstructed. Sixteen of our derived surrogates, including the MetaboHealth surrogate, showed significant associations with mortality, independent of relevant covariates.
Interpretation: The addition of our metabolic analyte-derived surrogates to the well-established epigenetic clock GrimAge demonstrates that our surrogates potentially represent valuable mortality signal.
Funding: BBMRI-NL, X-omics, VOILA, Medical Delta, NWO, ERC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378104 | PMC |
http://dx.doi.org/10.1016/j.ebiom.2024.105279 | DOI Listing |
J Neurosurg Case Lessons
September 2025
Department of Neurosurgery, Fleming Neuroscience Institute, Allentown, Pennsylvania.
Background: High-grade astrocytoma with piloid features (HGAP) was recently added to the WHO 2021 CNS classification system among the group of circumscribed astrocytic gliomas. These tumors present with high-grade piloid histology with similarities to glioblastoma. HGAPs in the pineal region become particularly challenging due to its deep location and proximity to deep venous structures, the midbrain, and the thalamus.
View Article and Find Full Text PDFFront Genet
August 2025
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: Prostatic diseases, consisting of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), pose significant health challenges. While single-omics studies have provided valuable insights into the role of mitochondrial dysfunction in prostatic diseases, integrating multi-omics approaches is essential for uncovering disease mechanisms and identifying therapeutic targets.
Methods: A genome-wide meta-analysis was conducted for prostatic diseases using the genome-wide association studies (GWAS) data from FinnGen and UK Biobank.
NAR Cancer
September 2025
Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland.
Noncoding RNAs play pivotal roles in tumorigenesis and cancer progression. Recent evidence has identified vault RNAs (vtRNAs) as critical regulators of cellular homeostasis. The human genome encodes four vtRNA paralogs, which are differentially expressed in cancer tissues and contribute to tumor development.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Stem Cell Research Center, Department of Pathology and Pathophysiology, School of Medicine, Tongji University, Shanghai, China.
Bladder cancer (BC) is a disease that predominantly affects older adults, with aging playing a critical role in its onset and progression. Age-associated phenomena, including immunosenescence and chronic inflammation, form a pro-tumor milieu, while genomic instability and epigenetic drift further increase cancer risk. The review highlights the dual role of DNA methylation in BC: global hypomethylation can activate transposable elements and oncogenes, whereas focal hypermethylation silences tumor-suppressor genes like CDKN2A, especially detrimental in older tissues that rely on these genes for senescence control.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, 64460, Mexico.
Emerging evidence highlights the potential of bioactive compounds, particularly polyphenols, as adjunctive therapeutic agents in the treatment of pancreatic cancer (PC), one of the most aggressive malignancies. This review focuses on epigallocatechin gallate (EGCG) and resveratrol due to their extensively documented anticancer activity, favorable safety profiles, and their unique ability to modulate multiple signaling pathways relevant to pancreatic tumorigenesis. Among polyphenols, these two have shown superior anti-cancer activity, epigenetic regulatory effects, and synergy with standard chemotherapies in preclinical pancreatic cancer models.
View Article and Find Full Text PDF